320 related articles for article (PubMed ID: 32065047)
21. Using real world data to support regulatory approval of drugs in rare diseases: A review of opportunities, limitations & a case example.
Gross AM
Curr Probl Cancer; 2021 Aug; 45(4):100769. PubMed ID: 34247834
[TBL] [Abstract][Full Text] [Related]
22. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
Wu J; Wang C; Toh S; Pisa FE; Bauer L
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
[TBL] [Abstract][Full Text] [Related]
23. Orphan drug designation and development in Japan: 25 years of experience and assessment.
Sakushima K; Takeda H; Aoi Y
Nat Rev Drug Discov; 2021 Dec; 20(12):893-894. PubMed ID: 33723413
[No Abstract] [Full Text] [Related]
24. Drugs Against Rare Diseases: Are The Regulatory Standards Higher?
Gobburu J; Pastoor D
Clin Pharmacol Ther; 2016 Oct; 100(4):322-3. PubMed ID: 27326701
[TBL] [Abstract][Full Text] [Related]
25. Accelerating access to treatments for rare diseases.
Dunoyer M
Nat Rev Drug Discov; 2011 Jun; 10(7):475-6. PubMed ID: 21701499
[TBL] [Abstract][Full Text] [Related]
26. Accelerating orphan drug development.
Coté TR; Xu K; Pariser AR
Nat Rev Drug Discov; 2010 Dec; 9(12):901-2. PubMed ID: 21119719
[TBL] [Abstract][Full Text] [Related]
27. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
Thorat C; Xu K; Freeman SN; Bonnel RA; Joseph F; Phillips MI; Imoisili MA
Pediatrics; 2012 Mar; 129(3):516-21. PubMed ID: 22371464
[TBL] [Abstract][Full Text] [Related]
28. Predictors of orphan drug approval in the European Union.
Heemstra HE; de Vrueh RL; van Weely S; Büller HA; Leufkens HG
Eur J Clin Pharmacol; 2008 May; 64(5):545-52. PubMed ID: 18210097
[TBL] [Abstract][Full Text] [Related]
29. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
30. Drug labels: a flawed source of data for studying orphan drug approvals.
Kesselheim AS; Avorn J
Clin Pharmacol Ther; 2012 Dec; 92(6):694; author reply 695. PubMed ID: 23073207
[No Abstract] [Full Text] [Related]
31. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
Stockklausner C; Lampert A; Hoffmann GF; Ries M
Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
[TBL] [Abstract][Full Text] [Related]
32. Drug development for exceptionally rare metabolic diseases: challenging but not impossible.
Putzeist M; Mantel-Teeuwisse AK; Wied CC; Hoes AW; Leufkens HG; de Vrueh RL
Orphanet J Rare Dis; 2013 Nov; 8():179. PubMed ID: 24237580
[TBL] [Abstract][Full Text] [Related]
33. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK
Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780
[TBL] [Abstract][Full Text] [Related]
34. A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?
Oo C; Rusch LM
J Clin Pharmacol; 2016 Mar; 56(3):257-9. PubMed ID: 26211513
[No Abstract] [Full Text] [Related]
35. FDA program could boost treatments for neglected diseases.
Traynor K
Am J Health Syst Pharm; 2008 Sep; 65(17):1595-6. PubMed ID: 18714098
[No Abstract] [Full Text] [Related]
36. Rare cancer trial design: lessons from FDA approvals.
Gaddipati H; Liu K; Pariser A; Pazdur R
Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
[TBL] [Abstract][Full Text] [Related]
37. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
Le TT
Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
[TBL] [Abstract][Full Text] [Related]
38. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
Xu K; Coté TR
Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612
[TBL] [Abstract][Full Text] [Related]
39. Patients left behind: Rare dermatologic conditions miss the orphan drug development boom.
Chavez A; Licholai G; Murrell DF
J Am Acad Dermatol; 2019 Oct; 81(4):1025-1026. PubMed ID: 30880063
[No Abstract] [Full Text] [Related]
40. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
